Home › Funds › MACKAY SHIELDS LLC › BMRN
MACKAY SHIELDS LLC position in BMRN
BIOMARIN PHARMACEUTICAL INC COM · Health Care
MACKAY SHIELDS LLC reported holding 26,468,000 shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM) in its Q3 2026 13F filing — a position valued at US$25.8M, representing 1.07% of its reported portfolio and ranking #40 among its reported holdings. MACKAY SHIELDS LLC has disclosed BMRN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR
How MACKAY SHIELDS LLC's BMRN position evolved
MACKAY SHIELDS LLC first disclosed a stake in BMRN in Q3 2023 at 9,891,000 shares (US$9.6M). The position peaked in Q2 2024 at 72,514,000 shares, worth US$69.5M. Across 13 filings, MACKAY SHIELDS LLC increased the stake 1 time(s), trimmed it 8 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 26,468,000 shares valued at US$25.8M. Notable position changes include a 720% increase in Q2 2024 (shares fell 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 9.89M | $9.59M | New |
| Q4 2023 | 9.07M | $8.94M | Reduce |
| Q1 2024 | 8.85M | $8.69M | Reduce |
| Q2 2024 | 72.51M | $69.48M | Add |
| Q3 2024 | 72.57M | $69.23M | Hold |
| Q4 2024 | 61.74M | $57.51M | Reduce |
| Q1 2025 | 54.93M | $51.84M | Reduce |
| Q2 2025 | 44.30M | $41.84M | Reduce |
| Q3 2025 | 35.21M | $33.45M | Reduce |
| Q4 2025 | 34.66M | $33.27M | Reduce |
| Q1 2026 | 26.50M | $25.56M | Reduce |
| Q2 2026 | 26.43M | $25.74M | Hold |
| Q3 2026 | 26.47M | $25.85M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BMRN and 13F data
BMRN (BIOMARIN PHARMACEUTICAL INC COM) is a Health Care company. 27 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$812.0M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BMRN
- PRIMECAP MANAGEMENT CO/CA/ 14.19M sh · $811.96M · Q2 2026
- Viking Global Investors 7.62M sh · $435.82M · Q2 2026
- VIKING GLOBAL INVESTORS LP 7.62M sh · $435.82M · Q2 2026
- Vestal Point Capital, LP 6.03M sh · $344.75M · Q2 2026
- Deep Track Capital, LP 3.31M sh · $189.25M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 111.50M sh · $108.89M · Q2 2026
More on MACKAY SHIELDS LLC
FAQ
How long has MACKAY SHIELDS LLC held BMRN?
MACKAY SHIELDS LLC has disclosed BMRN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is MACKAY SHIELDS LLC's current position in BMRN?
As of Q3 2026, MACKAY SHIELDS LLC holds 26.47M shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM), valued at $25.85M, representing 1.07% of its reported portfolio and ranking #40.
Has MACKAY SHIELDS LLC been buying or selling BMRN?
In the latest 13F filing (Q3 2026), MACKAY SHIELDS LLC held unchanged its position in BMRN. The position peaked in Q2 2024 at 72.51M shares.
Which other funds hold BMRN?
Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.